EYWN Stock Overview
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
bioMérieux S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €100.20 |
| 52 Week High | €106.20 |
| 52 Week Low | €84.92 |
| Beta | 0.14 |
| 1 Month Change | -0.10% |
| 3 Month Change | -3.51% |
| 1 Year Change | 6.60% |
| 3 Year Change | 0.85% |
| 5 Year Change | 43.04% |
| Change since IPO | 276.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| EYWN | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.2% | 2.1% | 0.5% |
| 1Y | 6.6% | -8.4% | 1.3% |
Return vs Industry: EYWN exceeded the German Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: EYWN exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| EYWN volatility | |
|---|---|
| EYWN Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EYWN has not had significant price volatility in the past 3 months.
Volatility Over Time: EYWN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 13,696 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests.
bioMérieux S.A. Fundamentals Summary
| EYWN fundamental statistics | |
|---|---|
| Market cap | €11.76b |
| Earnings (TTM) | €357.60m |
| Revenue (TTM) | €3.67b |
32.9x
P/E Ratio3.2x
P/S RatioIs EYWN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYWN income statement (TTM) | |
|---|---|
| Revenue | €3.67b |
| Cost of Revenue | €1.62b |
| Gross Profit | €2.06b |
| Other Expenses | €1.70b |
| Earnings | €357.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 05, 2024
| Earnings per share (EPS) | 3.03 |
| Gross Margin | 55.99% |
| Net Profit Margin | 9.73% |
| Debt/Equity Ratio | 9.9% |
How did EYWN perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield28%
Payout RatioDoes EYWN pay a reliable dividends?
See EYWN dividend history and benchmarks| bioMérieux dividend dates | |
|---|---|
| Ex Dividend Date | Jun 07 2024 |
| Dividend Pay Date | Jun 11 2024 |
| Days until Ex dividend | 42 days |
| Days until Dividend pay date | 46 days |
Does EYWN pay a reliable dividends?
See EYWN dividend history and benchmarks